Physicochemical Properties
| Molecular Formula | C13H14BRCLN2OS |
| Molecular Weight | 361.6851 |
| Exact Mass | 359.969 |
| CAS # | 1883548-91-1 |
| Related CAS # | ZLN024;723249-01-2 |
| PubChem CID | 91654626 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 19 |
| Complexity | 239 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | BrC1C([H])=C(C([H])([H])[H])C([H])=C([H])C=1OC([H])([H])C([H])([H])SC1=NC([H])=C([H])C([H])=N1.Cl[H] |
| InChi Key | MMQCYIMDROWWFE-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C13H13BrN2OS.ClH/c1-10-3-4-12(11(14)9-10)17-7-8-18-13-15-5-2-6-16-13;/h2-6,9H,7-8H2,1H3;1H |
| Chemical Name | 2-[2-(2-bromo-4-methylphenoxy)ethylsulfanyl]pyrimidine;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | AMPK α2β2γ1 0.13 μM (EC50) AMPK α1β1γ1 0.42 μM (EC50) AMPK α2β1γ1 0.95 μM (EC50) |
| ln Vitro | ZLN024 exhibits allosteric stimulation of both the inactive α1 subunit truncations, α1 (1-394) and α1 (1-335), as well as active AMPK heterotrimers, but not α1 (1-312). ZLN024 triggers AMPK activation by requiring Thr-172 to be pre-phosphorylated by a minimum of one upstream kinase. This prevents PP2Cα from dephosphorylating AMPK Thr-172. Without raising the ADP/ATP ratio, ZLN024 stimulates fatty acid oxidation and glucose uptake in L6 myotubes by activating AMPK. ZLN024, a new AMPK activator, is discovered through random screening against the AMPK α1β1γ1 heterotrimer using the well-established scintillation proximity assay (SPA) assay. In a concentration-dependent manner, ZLN024 directly activates recombinant AMPK α1β1η1 and its homologue α2β1η1. ZLN024 exhibits a 1.5-fold increase in α1β1η1 activity, with an EC50 of 0.42 µM, and a 1.7-fold rise in α2β1η1 activity, with an EC50 of 0.95 µM. ZLN024 also has an EC50 of 1.1 µM; 0.13 µM, directly activating recombinant AMPK α1β2γ1 by 1.7-fold[1]. |
| ln Vivo | For five weeks, ZLN024 at a dose of 15 mg/kg/day is given to C57BKS db/db mice by daily gavage; 250 mg/kg/day of Metformin (Met) is used as a positive control. When compared to the vehicle group, there is no discernible difference in the amount of food consumed or body weight over the treatment period. ZLN024 enhances glucose tolerance following a 4-week course of therapy. ZLN024 lowers blood glucose levels by 15% when fasting. Triacylglycerol, total cholesterol, and liver tissue weight are all reduced[1]. |
| References |
[1]. Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One. 2013 Aug 20;8(8):e72092. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ≥ 46 mg/mL (127.18 mM) H2O : < 0.1 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7648 mL | 13.8240 mL | 27.6480 mL | |
| 5 mM | 0.5530 mL | 2.7648 mL | 5.5296 mL | |
| 10 mM | 0.2765 mL | 1.3824 mL | 2.7648 mL |